Nimotop S (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral vessels. This reduces calcium entry into the cells, causing relaxation of the arterial wall, vasodilation, and improved cerebral perfusion, which provides neuroprotective benefits in the setting of hemorrhage.

The dosage of Nimotop S is determined by the prescribing clinician based on the patient’s condition, weight, and renal or hepatic function. The prescriber will set the appropriate strength, frequency, and duration according to current clinical guidelines.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nimotop S, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is distinguished by its high lipophilicity and preferential action on cerebral vessels, whereas many other calcium channel blockers affect systemic vasculature more broadly. This selectivity makes it particularly useful for preventing vasospasm after subarachnoid hemorrhage, a benefit not shared by all vasodilators.

Nimotop S should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Nimotop S is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration timing and frequency are set by the prescribing physician.

The most serious adverse events include severe hypotension, bradycardia, hepatic dysfunction, and rare allergic reactions. Patients should be monitored for signs of low blood pressure, abnormal heart rate, or liver enzyme changes, and any concerning symptoms should be reported promptly.

Nimotop S is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. Caution is advised for individuals with severe hypotension, advanced heart block, or significant hepatic impairment, and it should be avoided in these situations unless a physician determines that benefits outweigh risks.